Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

Haematologica

Volumn 99, Issue 4, 2014, Pages 779-787

  Ferrari, Silvia ^a   Palavra, Kristina ^a   Gruber, Bernadette ^a   Kremer Hovinga, Johanna A ^b   Knöbl, Paul ^c   Caron, Claudine ^d   Cromwell, Caroline ^e   Aledort, Louis ^e   Plaimauer, Barbara ^a   Turecek, Peter L ^a   Rottensteiner, Hanspeter ^a   Scheiflinger, Friedrich ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b UNIVERSITY OF BERN   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ANTIGEN ANTIBODY COMPLEX; AUTOANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADAM PROTEINS; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897471226     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.094151     Document Type: Article

References (44)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589-600.
2. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-94.
3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-84.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585-94.
5. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262-7.
6. Tsai HM, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006;95(5):886-92.
7. Shelat SG, Smith P, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006;4(8):1707-17.
8. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009;7(10):1703-10.
9. Pos W, Sorvillo N, Fijnheer R, Feys HB, Kaijen PH, Vidarsson G, et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica. 2011;96(11):1670-7.
10. Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta LA, Trisolini SM, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(8):1556-65.
11. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7):2815-22.
12. Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol. 2008;28(1):78-87.
13. Weissmann G. Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases. Bull NYU Hosp Jt Dis. 2009;67(3):251-3.
14. Toong C, Adelstein S, Phan TG. Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis. 2011;4:17-28.
15. Bayer AS, Theofilopoulos AN, Eisenberg R, Friedman SG, Guze LB. Thrombotic thrombocytopenic purpura-like syndrome associated with infective endocarditis. A possible immune complex disorder. JAMA. 1977; 238(5):408-10.
16. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood. 1977;50(3):413-7.
17. Celada A, Perrin LH. Circulating immune complexes in thrombotic thrombocytopenic purpura (TTP). Blood. 1978;52(4):855.
18. Neame PB, Hirsh J. Circulating immune complexes in thrombotic thrombocytopenic purpura (TTP). Blood. 1978;51(3):559-60.
19. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91(8):2839-46.
20. Rieger M, Ferrari S, Kremer Hovinga JA, Konetschny C, Herzog A, Koller L, et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost. 2006;95(2):212-20.
21. Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012;97 (2):297-303.
22. Yang S, Jin M, Lin S, Cataland S, Wu H. ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome. Haematologica. 2011;96(10):1521-7.
23. Ferrari S, Knoebl P, Kolovratova V, Plaimauer B, Turecek PL, Varadi K, et al. Inverse correlation of free and immune complexsequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(1):156-8.
24. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
25. Plaimauer B, Kremer Hovinga JA, Juno C, Wolfsegger MJ, Skalicky S, Schmidt M, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9(5):936-44.
26. Scheiflinger F, Knoebl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003; 102(9):3241-3.
27. El Shikh ME, Pitzalis C. Follicular dendritic cells in health and disease. Front Immunol. 2012;3(292):1-18.
28. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39(4):469-77.
29. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-25.
30. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol. 2013;190(8):4315-23.
31. van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844): 1554-7.
32. van der Zee JS, van SP, Aalberse RC. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol. 1986;137(11):3566-71.
33. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, van Mourik JA, et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost. 2006;96(3):295-301.
34. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95(9):1555-62.
35. Shmagel KV, Chereshnev VA. Molecular bases of immune complex pathology. Biochemistry (Mosc.). 2009;74(5):469-79.
36. Hussain A, Pankhurst T, Goodall M, Colman R, Jefferis R, Savage CO, et al. Chimeric IgG4 PR3-ANCA induces selective inflammatory responses from neutrophils through engagement of Fcgamma receptors. Immunology. 2009;128(2):236-44.
37. Filippone EJ. Idiopathic membranous nephropathy and IgG4: an interesting relationship. Clin Nephrol. 2013;Feb 5. [Epub ahead of print].
38. Mihai S, Chiriac MT, Herrero-Gonzalez JE, Goodall M, Jefferis R, Savage CO, et al. IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med. 2007;11(5):1117-28.
39. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15 (Suppl 1):S3.
40. Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009;83(4):365-72.
41. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481-90.
42. Schaller M, Studt JD, Voorberg J, Kremer Hovinga JA. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie. 2013;33(2):121-30.
43. Goyal J, Adamski J, Lima JL, Marques MB. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. J Clin Apher. 2013;28(6):390-4.
44. Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(9): 2053-62.